MARK2 and cancer: Therefore, we tested the effect of Merestinib, a multikinase inhibitor currently in cancer clinical trials18 (relevant to this study shown to be active against receptor tyrosine kinases, serine/threonine kinases, inhibit MNK induced phosphorylation of eIF4E) to target this translational signaling as a single agent and in combination with Lapatinib.